We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has argenex SE (ARGX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
argenex SE is one of 913 individual stocks in the Medical sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. argenex SE is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ARGX's full-year earnings has moved 12.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ARGX has returned about 3.7% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.8% on a year-to-date basis. This means that argenex SE is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Agilent Technologies (A - Free Report) . The stock is up 3.3% year-to-date.
The consensus estimate for Agilent Technologies' current year EPS has increased 1.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, argenex SE belongs to the Medical - Biomedical and Genetics industry, which includes 438 individual stocks and currently sits at #92 in the Zacks Industry Rank. On average, this group has gained an average of 3.6% so far this year, meaning that ARGX is performing better in terms of year-to-date returns.
Agilent Technologies, however, belongs to the Medical - Products industry. Currently, this 84-stock industry is ranked #160. The industry has moved -17% so far this year.
Investors with an interest in Medical stocks should continue to track argenex SE and Agilent Technologies. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has argenex SE (ARGX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
argenex SE is one of 913 individual stocks in the Medical sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. argenex SE is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ARGX's full-year earnings has moved 12.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ARGX has returned about 3.7% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 2.8% on a year-to-date basis. This means that argenex SE is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Agilent Technologies (A - Free Report) . The stock is up 3.3% year-to-date.
The consensus estimate for Agilent Technologies' current year EPS has increased 1.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, argenex SE belongs to the Medical - Biomedical and Genetics industry, which includes 438 individual stocks and currently sits at #92 in the Zacks Industry Rank. On average, this group has gained an average of 3.6% so far this year, meaning that ARGX is performing better in terms of year-to-date returns.
Agilent Technologies, however, belongs to the Medical - Products industry. Currently, this 84-stock industry is ranked #160. The industry has moved -17% so far this year.
Investors with an interest in Medical stocks should continue to track argenex SE and Agilent Technologies. These stocks will be looking to continue their solid performance.